|Mr. Michael J. Valentino||Exec. Chairman||353.12k||N/A||1954|
|Ms. Natasha Giordano||CEO, Pres & Director||749.75k||N/A||1960|
|Ms. Rita M. O'Connor C.P.A., CPA||CFO and Head of Manufacturing & Supply Chain||552.92k||N/A||1968|
|Mr. Ronald R. Zimmerman||Founder & Sr. Advisor||N/A||N/A||1953|
|Mr. Tom Long||VP of Manufacturing & Technical Operations||N/A||N/A||N/A|
|Ms. Joanne Cotignola||VP of Marketing||N/A||N/A||N/A|
|Mr. Patrick M. Lonergan||Member of Chief Exec. Officer Advisory Group||N/A||N/A||1935|
|Mr. Charles Edmund Sheedy C.F.A., CFA||Member of Chief Exec. Officer Advisory Group||N/A||N/A||1947|
|Mr. Harris Kaplan MBA||Member of Chief Exec. Officer Advisory Group||N/A||N/A||1952|
|Mr. Gary L. Mossman||Sr. Advisor||N/A||N/A||1941|
PLx Pharma Inc., a specialty pharmaceutical company, focuses on developing the PLxGuard drug delivery system to provide various products in the United States. The company's lead product candidates are Vazalore 325 mg and Vazalore 81 mg, which are formulations of aspirin that use the PLxGuard delivery system, which provides patients with vascular disease and diabetic patients who are candidates for aspirin therapy based on physician recommendation, with fast, reliable, and predictable platelet inhibition as compared to enteric-coated aspirin, as well as reduces the risk of stomach erosions and ulcers as compared with immediate-release aspirin, after seven days of treatment. Its product pipeline also includes other oral nonsteroidal anti-inflammatory drugs using the PLxGuard drug delivery system, such as PL1200 Ibuprofen 200 mg and PL1200 Ibuprofen 400 mg, which are in Phase I clinical stage for pain and inflammation, as well as PL1100 Ibuprofen 400 mg. PLx Pharma Inc. was founded in 2002 and is headquartered in Sparta, New Jersey.
PLx Pharma Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.